The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Responses to COVID-19 vaccination in patients with MDS and AML
In this video, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, briefly highlights the response of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) to the COVID-19 vaccine. Dr Sallman mentions the need to obtain more data in the future on survival and risk of hospitalization, and emphasizes the importance of current data, which strongly supports vaccination in patients with hematological malignancies. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
